ALK and neuroblastoma: For a patient with neuroblastoma zccs51 harboring an ALKF1245I mutation and clinical PR to the ALK inhibitor, lorlatinib, the cognate mouse and zebrafish PDX models both demonstrated response to lorlatinib (Fig. 2C; Supplementary Fig. S3C).